Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002
暂无分享,去创建一个
[1] I. Macdougall,et al. PRE-dialysis survey on anaemia management. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] C. Zoccali,et al. Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. , 2002, Journal of the American Society of Nephrology : JASN.
[3] J. Griffith,et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. , 2002, Journal of the American College of Cardiology.
[4] B. Astor,et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). , 2002, Archives of internal medicine.
[5] A. Levin,et al. The relationship of haemoglobin level and survival: direct or indirect effects? , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] R. Foley,et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. , 2002, Journal of the American Society of Nephrology : JASN.
[7] L. Stevens,et al. Should Hemoglobin be Normalized in Patients with Chronic Kidney Disease? , 2002, Seminars in dialysis.
[8] N. Ahsan,et al. Editorials: Dialysis Access Failure: An Indication for Immediate Kidney Transplantation , 2002, Seminars in dialysis.
[9] S. Klarenbach,et al. Reduced Requirement for Erythropoietin with Quotidian Hemodialysis Therapy , 2002, ASAIO journal.
[10] M. Rocco,et al. Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] S. Kihara,et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[12] B. Lindholm,et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. , 2002, Journal of the American Society of Nephrology : JASN.
[13] P. Vallance. Importance of asymmetrical dimethylarginine in cardiovascular risk , 2001, The Lancet.
[14] C. Zoccali,et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.
[15] P. Fein,et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] J. Blacher,et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. , 2001, Journal of the American Society of Nephrology.
[17] A. Collins,et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. , 2001, Journal of the American Society of Nephrology : JASN.
[18] A. Kausz,et al. Anemia: an early complication of chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] K. Eckardt. Anaemia in end-stage renal disease: pathophysiological considerations. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] K. Eckardt. After 15 years of success--perspectives of erythropoietin therapy. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] M. Kikuchi,et al. Five‐Year Survival of Older People with Anemia: Variation with Hemoglobin Concentration , 2001, Journal of the American Geriatrics Society.
[22] A. Cerami,et al. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. , 2001, Seminars in hematology.
[23] G. Stabellini,et al. Erythropoietin and Cardiocirculatory Condition in Aged Patients with Chronic Rena l Failure , 2001, Nephron.
[24] I. Shapira,et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.
[25] G. Thomas. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. , 2001, Seminars in oncology.
[26] P. Lewczuk,et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Blacher,et al. Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure , 2001, Circulation.
[28] J. Fink,et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] B Fellström,et al. Impaired endothelium-dependent vasodilatation in renal failure in humans. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[30] R. Brant,et al. Poor long-term survival after coronary angiography in patients with renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[31] C. Zoccali,et al. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] M. Gassmann,et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[33] P Ghezzi,et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Yee,et al. Risks associated with renal dysfunction in patients in the coronary care unit. , 2000, Journal of the American College of Cardiology.
[35] A. Levin,et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. , 2000, Kidney international.
[36] Mohamed,et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. , 2000, Kidney international.
[37] O. Sommerburg,et al. Oxidation parameters in complete correction of renal anemia. , 2000, Clinical nephrology.
[38] Avid,et al. THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .
[39] G. Remuzzi,et al. Physiology and pathophysiology of nitric oxide in chronic renal disease. , 1999, Proceedings of the Association of American Physicians.
[40] M. Iruela-Arispe,et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. , 1999, Development.
[41] J. Singer,et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] E. Ritz,et al. Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.
[43] E. Morishita,et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] W. Owen,et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. , 1997, Journal of the American Society of Nephrology : JASN.
[45] David C. Murray,et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[46] E. Borda,et al. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: Signal transduction pathways , 1996, Journal of cellular physiology.
[47] J. Singer,et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[48] W. Curran,et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] David C. Murray,et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. , 1995, Kidney international.
[50] E. Borda,et al. Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. , 1995, Nephron.
[51] David C. Murray,et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.
[52] P. Parfrey,et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. , 1994, Journal of the American Society of Nephrology : JASN.
[53] E. Ritz,et al. Reduced capillary density in the myocardium of uremic rats--a stereological study. , 1992, Kidney international.
[54] A. Raine,et al. Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia. , 1992, Kidney international.
[55] M. Safar,et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. , 1989, Kidney international.